# Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML

> **NCT07451912** · PHASE1,PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 29 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)
- CEBPA Mutation
- Unfit, New-diagnosis AML

## Interventions

- **DRUG:** Venetoclax + Hypomethylating Agents + Low-Dose Cytarabine for CEBPA-Mutated AML (Unfit Patients)

## Key facts

- **NCT ID:** NCT07451912
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-15
- **Primary completion:** 2027-09
- **Final completion:** 2027-12
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07451912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07451912, "Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT07451912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*